- Home
- DAWN vs FOR Comparison
DAWN vs FOR Comparison
Compare DAWN & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- FOR
- Stock Information
- Founded
- DAWN 2018
- FOR 2005
- Country
- DAWN United States
- FOR United States
- Employees
- DAWN N/A
- FOR N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- FOR Real Estate
- Sector
- DAWN Health Care
- FOR Finance
- Exchange
- DAWN Nasdaq
- FOR Nasdaq
- Market Cap
- DAWN 1.3B
- FOR 1.4B
- IPO Year
- DAWN 2021
- FOR 2007
- Fundamental
- Price
- DAWN $12.24
- FOR $24.25
- Analyst Decision
- DAWN Strong Buy
- FOR Strong Buy
- Analyst Count
- DAWN 7
- FOR 4
- Target Price
- DAWN $36.33
- FOR $39.25
- AVG Volume (30 Days)
- DAWN 1.1M
- FOR 147.9K
- Earning Date
- DAWN 02-24-2025
- FOR 01-21-2025
- Dividend Yield
- DAWN N/A
- FOR N/A
- EPS Growth
- DAWN N/A
- FOR N/A
- EPS
- DAWN N/A
- FOR 3.56
- Revenue
- DAWN $101,953,000.00
- FOR $1,453,900,000.00
- Revenue This Year
- DAWN N/A
- FOR $9.38
- Revenue Next Year
- DAWN $35.22
- FOR $11.69
- P/E Ratio
- DAWN N/A
- FOR $7.53
- Revenue Growth
- DAWN N/A
- FOR N/A
- 52 Week Low
- DAWN $11.13
- FOR $23.80
- 52 Week High
- DAWN $18.07
- FOR $40.92
- Technical
- Relative Strength Index (RSI)
- DAWN 45.74
- FOR 34.19
- Support Level
- DAWN $11.13
- FOR $24.81
- Resistance Level
- DAWN $12.74
- FOR $27.75
- Average True Range (ATR)
- DAWN 0.51
- FOR 0.83
- MACD
- DAWN 0.06
- FOR 0.14
- Stochastic Oscillator
- DAWN 51.15
- FOR 11.39
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.